How a Nurse Practitioner Protect a Client from Being Harmed by the Vericiguat Medication
People may ask why drugs alert and recalls are necessary. They are necessary since they safeguard patients from the maltreatment that may be triggered to them by medications defective. Nurse practitioners can protect a client from being harmed by the vericiguat medication by informing the Medicine and Healthcare Regulatory Agency (MHRA) of any quality defect suspected, which would result in restriction or a recall (Lowe, 2018). Nurse practitioners can also follow checklists and basic care performance to ensure that client is protected from being harmed by the drug vericiguat.
Description, Usage, and Dosage of Vericiguat Drug
Vericiguat is a cyclase guanylate soluble stimulator designated to lessen the danger of failure of the heart and cardiovascular death (Rana et al., 2019). Verquvo tablets contain Vericiguat, which is a guanylate cyclase soluble stimulator. It is a white to yellowish powder which is slightly soluble in acetone and freely soluble in dimethyl sulfoxide. The Vericiguat drug is present as tablets for oral administration. The coating film contains titanium dioxide, talc, and hypromellose. Vericiguat is an oral drug used to reduce the risk of heart failure and cardiovascular death. The preliminary dosage is 2.5mg vocally once every day with diet. One should target a dose of 10mg daily to reach the maintenance target by doubling the dose every two weeks.
Side Effects of Vericiguat Drug
Vericiguat causes allergic reactions such as breathing difficulties, hives, face, lips, and swelling. The drugs also cause a feeling of lightheadedness and can lead to a lack of blood in the body. The most common side effects are suffering from low blood pressure and anemia.
Who Can Use Vericiguat Drug
Vericiguat drugs can be used by certain adults with chronic heart failure to reduce the need to be in hospital and also to lower the death risk (Gras, 2018). It is used by a grown-up with chronic symptomatic HF with a fraction less than 45% ejection.
References
Gras, J. (2018). Vericiguat. Soluble guanylate cyclase (sGC) activator, Heart failure therapy.Drugs of the Future, 43(8), 573. Web.
Lowe, G. (2018). Nurse practitioners can influence, shape, and reform healthcare.The Journal for Nurse Practitioners, 14(2), 124. Web.
Rana, K., Reid, J., Choksi, R., Lewis, T., & Goldfaden, R. (2019). Praliciguat. Soluble guanylate cyclase activator, Treatment of heart failure with preserved ejection fraction, Treatment of diabetic nephropathy.Drugs of the Future, 44(4), 277. Web.